The University of Kansas Health System St. Francis Campus has introduced artificial intelligence to improve early lung cancer detection.
Announced on Tuesday, the hospital is the first in Topeka to adopt the technology. It uses Eon’s AI powered system to analyze incidental findings. These findings often appear when patients undergo scans for other medical reasons, and lung nodules can sometimes be overlooked.
“This technology gives our care teams the clinical intelligence we need to act on findings immediately,” said Abhishek Chakraborti, MD.
He explained that the system ensures patients with lung nodules receive evidence based follow up care. In addition, it provides guidance even when radiologists’ reports do not include specific recommendations.
The program aims to prevent overlooked findings, surface patients who need additional review, and support long term monitoring. Furthermore, early intervention can significantly improve outcomes for those with concerning nodules.
“If a nodule looks concerning, we have the tools and expertise to move quickly,” said Vimalkumar Patel, MD.
The hospital emphasized that this program allows Topeka patients to access advanced lung care locally. Previously, many patients needed to travel to larger metropolitan areas for similar services. However, with this program, they can receive comprehensive treatment closer to home.
Within the lung nodule program, specialists coordinate each patient’s care from detection through next steps. Consequently, patients experience less confusion, faster answers, and smoother pathways to treatment. In addition, teams can move patients into advanced care when needed without delay.
Read more: Breath Diagnostics adopts state-of-the-art mass spectrometer device for lung screening
Read more: Breath Diagnostics tech achieves pneumonia prediction breakthrough in peer-reviewed study
AI has found broad use in fight against lung cancer
Artificial intelligence is increasingly transforming cancer diagnosis and treatment, offering faster, more accurate, and personalized care. AI applications span early detection, drug discovery, and precision medicine, enhancing outcomes and efficiency in oncology.
In early detection, AI algorithms analyze medical imaging to identify subtle patterns indicative of cancer. For instance, DeepHealth’s ProFound AI suite aids radiologists in detecting breast cancer by evaluating mammograms for density and risk factors. Similarly, Skin Analytics’ AI tool, Derm, swiftly assesses skin lesions for melanoma, reducing wait times and improving diagnostic accuracy.
In drug discovery, companies like Recursion Pharmaceuticals (NASDAQ: RXRX) utilize AI to predict effective drug candidates, accelerating the development of oncology treatments. Furthermore, Eli Lilly’s (NYSE: LLY) TuneLab platform enables AI driven drug discovery, helping smaller biotech firms develop cancer therapies more efficiently.
Precision medicine is another area where AI excels. ArteraAI offers predictive tests for prostate cancer, personalizing treatment plans based on individual tumor characteristics. Meanwhile, Breath Diagnostics has developed OneBreath technology, a non-invasive breath analysis system that uses AI through its microreactor to detect lung cancer early.
These advancements underscore AI’s pivotal role in revolutionizing cancer care, making it more accessible, timely, and tailored to individual patient needs. By combining technology with coordinated care, the healthcare industry aims to improve early diagnosis, streamline treatment pathways, and enhance long term outcomes for cancer patients.
.
